Watchlist Price Alert

TScan Therapeutics Inc. (TCRX)

NASDAQ: TCRX · Real-Time Price · USD

1.27

-0.11 (-7.97%)

At close: May 09, 2025, 3:59 PM

1.31

3.15%

After-hours: May 09, 2025, 05:48 PM EDT

-7.97% (1D)

Bid	1.25
Market Cap	71.87M
Revenue (ttm)	2.82M
Net Income (ttm)	-127.5M
EPS (ttm)	-1.14
PE Ratio (ttm)	-1.11
Forward PE	-1.02
Analyst	Buy

Ask	1.31
Volume	203,379
Avg. Volume (20D)	469,177
Open	1.37
Previous Close	1.38
Day's Range	1.27 - 1.43
52-Week Range	1.02 - 9.69
Beta	1.06

About TCRX

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol TCRX

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for TCRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

TScan Therapeutics has released their quartely earnings on May 6, 2025:

Revenue of $2.17M exceeds estimates by $1.09M, with 283.57% YoY growth.

EPS of -0.26 exceeds estimates by 0.02, with 18.75% YoY growth.

News

5 days ago · zacks.com

TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.32 per share a year ago.

2 months ago · seekingalpha.com

TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025

Additional data from phase 1 ALLOHA study, using TSC-101 for the treatment of patients with hematological malignancies of those undergoing allogeneic haploidentical HSCT, expected by end of 2025. Barr...

2 months ago · zacks.com

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.21 per share a year ago.